Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Phillip Esce

Neurological Surgery Spartanburg, SC Medical Doctor

NPI 1457322406 CMS profile 20873

303 E Wood St, Spartanburg, SC 29303

Open in the dashboard

General payments

$32,361

52 records reported · program years 2019–2025

Research payments

$333,720

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Phillip Esce of Spartanburg, SC is reported in the CMS Open Payments database as having received $32,361 across 52 general payments and $333,720 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,540 11
2024 General $4,297 7
2023 General $18,473 22
2022 General $868 7
2022 Research $30,240 1
2021 General $18 1
2021 Research $63,840 1
2020 General $500 1
2020 Research $86,240 1
2019 General $666 3
2019 Research $153,400 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Esce
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Phillip Esce were reported at $7,540. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Phillip Esce Neurological Surgery median Middle half National median
2019 $666 $582 $138–$3,006 $163
2020 $500 $294 $76–$2,174 $114
2021 $18 $387 $105–$2,432 $132
2022 $868 $542 $139–$2,989 $149
2023 $18,473 $534 $145–$2,697 $160
2024 $4,297 $574 $155–$3,046 $164
2025 $7,540 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nexxt Spine LLC $29,305 29 payments
  2. IMPLANET America, Inc. $1,239 4 payments
  3. Spine Wave, Inc. $1,095 2 payments
  4. Abbott Laboratories $237 7 payments
  5. RTI Surgical, Inc. $166 2 payments
  6. Alphatec Spine, Inc $102 1 payment
  7. Seaspine Orthopedics Corporation $82 1 payment
  8. Inari Medical, Inc. $41 1 payment
  9. Smith+Nephew, Inc. $28 1 payment
  10. Intrinsic Therapeutics $21 1 payment
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $11,630 10 payments
  2. Consulting Fee $11,115 7 payments
  3. Royalty or License $7,049 2 payments
  4. Food and Beverage $2,568 33 payments
Products named General payments · program years 2019–2025
  1. SI System $17,497 15 payments
  2. Struxxure MCS System $7,049 2 payments
  3. Nexxt Matrixx SI Helixx $6,033 2 payments
  4. Connexx System $5,625 1 payment
  5. Struxxure MCS $2,490 1 payment
  6. Matrixx SI $2,490 1 payment
  7. TESTA TP PIVOTING SPACER SYSTEM $1,000 1 payment
  8. SI Development $717 2 payments
  9. Nexxt Spine Product Offerings $505 3 payments
  10. Nexxt Spine Cadaver Lab Product Follow Up $470 2 payments
  11. Other $1,655 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Allied Spinal Industries $333,720 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

847

Median for Neurosurgery: 83

Drug cost

$8,543

Median for Neurosurgery: $872

Branded share of claims

26.8%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 177 $2,048
Naloxone Hcl Generic 20 $1,527
Tizanidine Hcl Generic 182 $1,415
Oxycodone Hcl Generic 112 $795
Methocarbamol Generic 57 $505
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $464
Pregabalin Generic 24 $365
Cephalexin Generic 52 $351
Gabapentin Generic 41 $300
Methylprednisolone Generic 39 $273

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$310,971

Of which drugs: $204

Medicare patients

717

Average age 74

Services billed

3,209

421 women, 296 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Depression 28%
Chronic kidney disease 25%
Ischemic heart disease 21%
Osteoporosis 18%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadobenate dimeglumine (multihance), per ml A9577 Office 13 141 $202

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

56 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record